Developer docs
API playgroundTry for free, no card

Search company profiles

InSphero

Full company profile

uuid00022sp

Namestring
InSphero
Legal namestring
InSphero AG
Websiteurl
insphero.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

InSphero AG is a Swiss privately held biotechnology company founded in 2009 and headquartered in Schlieren, Switzerland, with a regional operating office in Brunswick, Maine, serving the United States and Canada. The company develops 3D in vitro cell-based assay platforms — combining scaffold-free Akura™ microplates, Akura™ Organ-on-Chip microphysiological systems (Flow, Immune Flow, Twin), Gri3D® hydrogel microcavity plates (acquired from DOPPL SA / Sun Bioscience in November 2025), ARCTis™ cryopreserved 3D tumor models, and the RealBrain® neural platform co-developed with Tessara — for pharmaceutical and biotechnology customers seeking human-relevant, non-animal alternatives to preclinical drug testing. Layered on this technology base are high-content imaging (strengthened by the May 2026 PhenoVista Biosciences acquisition), TempO-Seq-based RNA sequencing modules, AI-enabled fibrosis digital pathology (via PharmaNest partnership), and a portfolio of regulatory-relevant NAMs aligned with the FDA's April 2025 Roadmap to Reducing Animal Testing and NIH organoid standardization initiatives.

InSphero operates a dual-track commercial model. Product revenue comes from catalog sales of Akura™ and Gri3D® microplates, Akura™ Organ-on-Chip platforms, the Akura™ Tilting Stand, InSphero Incubox™, and ready-to-use 3D InSight™ microtissues (liver, islet, tumor) shipped via the proprietary InFloat™ solution, distributed through the company's own e-commerce storefront (shop.insphero.com) and an authorized distributor network. Service and contract-research revenue comes from quote-based 3D InSight™ engagements — Liver Microtissues, DILI Service, DIGIT™ GI Toxicity, Translational and Investigative Toxicology, RNA-Seq reports, MASH/MASLD screening, immuno-oncology screening, therapeutic modality screening, and tumor penetration screening — priced via dedicated service schedule pages rather than published price lists.

The go-to-market is sales-led and B2B, targeting enterprise pharmaceutical and biotechnology R&D buyers through direct regional offices in Switzerland and the United States, an event-driven presence at industry venues (e.g., BIO Convention 2026 NAMs Industry Mixer), a scientific content-marketing program (peer-reviewed publications, white papers, webinars, application notes), and partnership-driven co-marketing with PharmaNest, Tessara, and ETH Zurich. The company is a founding member of IAMPS (Industry Alliance for Microphysiological Systems, expected operational Q2 2026) and holds ISO 9001:2015 certification (2023–2026). Its primary end-users are pharma/biotech R&D organizations (estimated ~55–59% of organ-on-chip demand), with secondary reach into academic and government research institutions (including a peer-reviewed collaboration with the U.S. FDA's National Center for Toxicological Research).

Short descriptiontext

InSphero AG is a Swiss biotechnology company that develops 3D in vitro microtissue models, organ-on-chip platforms, and contract research services for pharmaceutical and biotechnology customers seeking human-relevant, non-animal alternatives for preclinical drug discovery and safety assessment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D in vitro models, organ-on-chip platforms, drug safety testing, microphysiological systems, preclinical toxicology services
Industry4 codes
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
3D In Vitro Cell Culture and Organ-on-Chip Technologies
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product sales (3D cell culture tools and microplates)
TypeOne Time License
Description

One-time/perpetual-license product sales of catalog items including Akura™ 96 and 384 Spheroid Microplates, Akura™ PLUS Hanging Drop System, Gri3D® Hydrogel Microcavity Plates, Akura™ Organ-on-Chip platforms (Flow, Immune Flow, Twin), Akura™ Tilting Stand, InSphero Incubox™, and ready-to-use spheroids/kits. Distributed via own online shop (shop.insphero.com) and authorized distributors.

insphero.com
23D InSight™ Contract Research / Services
TypeProfessional Services
Description

Fee-for-service offerings including 3D InSight™ Liver Microtissues, DILI Service Schedule, DIGIT Service Schedule, 3D InSight™ Translational Toxicology Service, 3D InSight™ Investigative Toxicology, species-specific toxicology, RNA-Seq sample reports, and 3D InSight™ Human Beta Cell Proliferation Service for pharma/biotech customers.

insphero.com
3Ready-to-use spheroids and 3D cell culture kits
TypeHardware Sales
Description

Catalogue product sales of assay-ready 3D InSight™ Microtissues (liver, islet, tumor) and kits shipped via the proprietary InFloat™ shipping solution, used by pharma, biotech, and academic customers.

insphero.com
4Custom assay development and partnerships
TypeManaged Services
Description

Co-development, custom assay, and partnership revenue streams — exemplified by PharmaNest collaboration for AI-powered single-fiber digital pathology in fibrosis, and PhenoVista acquisition enabling high-content imaging assay services.

insphero.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Catalog products (Akura™ microplates, Gri3D® plates, Akura™ Organ-on-Chip platforms, ready-to-use spheroids/kits) — quote-based via shop.insphero.com and distributors.
ModelOtherBilling cadencePay-as-you-go
Notes

No public price list; transactions handled through online shop and authorized distributor network.

insphero.com
23D InSight™ services (Liver Microtissues, DILI, DIGIT, RNA-Seq, Investigative Toxicology) — quote-based service engagements with production/scheduling calendars.
ModelOtherBilling cadencePay-as-you-go
Notes

No public pricing; scheduled via dedicated service schedule pages (Production Schedule, DILI Service Schedule, DIGIT Service Schedule).

insphero.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
13D InSight™
Description

Branded service and product line for InSphero's 3D in vitro assays and microtissue offerings (e.g., 3D InSight™ Liver Microtissues, DILI Service, Translational Toxicology Service).

insphero.com
+7 more records
Core offering1 text field

InSphero develops and sells proprietary 3D in vitro cell-based assay platforms — including scaffold-free Akura™ microplates, Gri3D® hydrogel microcavity plates, and Akura™ Organ-on-Chip microphysiological systems — alongside ready-to-use microtissues, cryopreserved 3D tumor models (ARCTis™), and contract research services (3D InSight™) for pharmaceutical and biotechnology drug discovery, toxicology, and safety assessment. The integrated product-plus-service model enables scalable, human-relevant, non-animal preclinical testing across liver safety, oncology/immuno-oncology, islet biology, gastrointestinal toxicity, fibrosis, and neuroscience applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Akura™ 96 Spheroid Microplate enables manual medium exchange under 2 minutes
+4 more records
Product overview1 text field

InSphero offers a single, integrated 3D in vitro platform for non-animal drug discovery and safety assessment, built around three core technologies—Akura™ Microplate Technology, Akura™ Organ-on-Chip Technology, and Gri3D® Hydrogel Microcavity Technology (acquired from DOPPL SA / Sun Bioscience)—together with the RealBrain® neural platform (partnered with Tessara) and a TempO-Seq-based RNA sequencing module. On top of this technology base, InSphero runs a portfolio of ready-to-use products and services under the 3D InSight™ brand, including 3D InSight™ Human and Species-Specific Liver Microtissues, the DILI Reference Database, 3D InSight™ Human Islet Microtissues, ARCTis™ cryopreserved patient-derived 3D tumor models, the 3D InSight™ GI Toxicity Screening Platform, and the DIGIT™ GI platform co-developed with DOPPL. Service modules—3D InSight™ Investigative Toxicology, Translational Toxicology, Predictive DILI, MASH/MASLD screening, immuno-oncology screening, antibody penetration, and tumor penetration screening—combine these microtissues with high-content imaging and AI/machine-learning analytics (notably via the PhenoVista Biosciences acquisition) to deliver human-relevant liver safety, islet biology, oncology, immunology, fibrosis, and gastrointestinal toxicology solutions for pharmaceutical and biotech R&D.

Product and service27 records
1Akura™ 96 Spheroid Microplate
Category3D Cell Culture Microplates
Description

96-well Akura™ microplate optimized for scaffold-free spheroid culture, enabling manual medium exchange in under two minutes and high-content imaging; sold to pharma, biotech, and academic laboratories for 3D cell culture workflows.

2Akura™ 384 Spheroid Microplate
Category3D Cell Culture Microplates
Description

384-well Akura™ microplate for high-throughput scaffold-free 3D spheroid culture and screening workflows; sold to laboratories requiring scalable high-throughput 3D assays.

3Akura™ PLUS Hanging Drop System
Category3D Cell Culture Tools
Description

Hanging drop system for generating and maintaining uniform 3D spheroids in a standardized, scalable format for research laboratories.

4Gri3D® Hydrogel Microcavity Plates
Category3D Cell Culture Microplates
Description

Standardized Gri3D® hydrogel microcavity plates supporting reproducible organoid and 3D microtissue culture with broad plate-reader and automation compatibility; sold to pharma, biotech, and academic researchers.

5Akura™ Flow Organ-on-Chip System
CategoryOrgan-on-Chip Platforms
Description

Perfusion microphysiological system for long-term 3D tissue culture supporting drug metabolism, DDI prediction, and chronic exposure studies; sold to pharmaceutical researchers.

6Akura™ Immune Flow Organ-on-Chip System
CategoryOrgan-on-Chip Platforms
Description

Microfluidic organ-on-chip that maintains immune cells in circulation while interacting with 3D tissue models for over six days via gravity-driven tilting; targets immuno-oncology and antibody-based cancer treatment research.

7Akura™ Twin Organ-on-Chip Platform
CategoryOrgan-on-Chip Platforms
Description

Dual-channel microphysiological platform within the Akura™ organ-on-chip family for parallel tissue conditions or multi-tissue co-culture; sold to researchers requiring comparative or multi-tissue in vitro studies.

8Akura™ Tilting Stand
CategoryOrgan-on-Chip Accessories
Description

Mechanical tilting stand that drives gravity-mediated perfusion in Akura™ Organ-on-Chip platforms (e.g., Akura Immune Flow), enabling pump-free circulation of immune cells.

9InSphero Incubox™
Category3D Cell Culture Accessories
Description

Incubation accessory designed to maintain optimal conditions for 3D microtissue handling and short-term culture outside the incubator.

10Akura™ 3D SureKit
Category3D Cell Culture Kits
Description

Ready-to-use 3D cell culture kit built on Akura™ technology for standardized liver and other 3D assay workflows.

11ARCTis™ Cryopreserved 3D Tumor Models
Category3D Microtissue Products
Description

Cryopreserved, ready-to-use 3D tumor spheroid models for cancer research, enabling fast and reproducible testing of small molecules, biologics, and antibody penetration.

12Ready-to-use Spheroids and 3D Cell Culture Kits
Category3D Microtissue Products
Description

Catalogue of ready-to-use spheroids, microtissues, and 3D cell culture kits delivered assay-ready with InFloat™ shipping solution; sold to pharma, biotech, and academic customers.

133D InSight™ Human Liver Microtissues
Category3D Microtissue Products
Description

Assay-ready, cryopreserved and ready-to-use 3D human liver microtissues used for DILI screening, MASH/MASLD modeling, and predictive liver toxicology.

143D InSight™ Species-Specific Liver Microtissues
Category3D Microtissue Products
Description

Assay-ready liver spheroids from multiple species for cross-species translational hepatotoxicity and safety pharmacology assessments.

153D InSight™ Human Islet Microtissues
Category3D Microtissue Products
Description

3D human islet microtissues for diabetes, beta-cell proliferation, and metabolic disease drug discovery.

163D InSight™ GI Toxicity Screening Platform
Category3D Microtissue Products
Description

3D in vitro gastrointestinal toxicity screening platform using human intestinal organoids in Akura™/Gri3D® plates for drug-induced GI toxicity assessment.

173D InSight™ Patient-derived Primary Tumor Spheroids Platform
Category3D Microtissue Products
Description

High-throughput platform of patient-derived primary tumor spheroids for pre-clinical oncology drug discovery and screening.

18DIGIT™ Platform
CategoryOrgan-on-Chip Platforms
Description

Microphysiological gastrointestinal platform co-developed with DOPPL SA that combines organoid technology with InSphero's assay infrastructure for gastrointestinal research applications.

193D InSight™ DILI Testing Service
CategoryContract Research Services
Description

Advanced predictive drug-induced liver injury (DILI) testing service using 3D InSight™ liver microtissues and reference compound datasets; for pharmaceutical and biotech customers.

203D InSight™ Investigative Toxicology Service
CategoryContract Research Services
Description

Custom investigative liver safety services leveraging 3D liver microtissues for mechanism-of-action and hazard characterization studies.

213D InSight™ Translational Toxicology Service
CategoryContract Research Services
Description

Translational hepatotoxicity service combining cross-species liver microtissues, RNA-Seq, and human-relevant in vitro data to support drug development.

223D In Vitro MASH Screening Service
CategoryContract Research Services
Description

In vitro MASH (metabolic dysfunction-associated steatohepatitis) screening service for lead selection using 3D liver spheroid models.

233D InSight™ Immuno-Oncology Screening Service
CategoryContract Research Services
Description

3D in vitro immuno-oncology screening platform using immune-competent tumor microtissues for evaluating checkpoint inhibitors, T-cell killing, and cell therapies.

243D InSight™ Therapeutic Modality Screening Service
CategoryContract Research Services
Description

Service for profiling therapeutic modalities (small molecules, antibodies, ADCs) against 3D tumor spheroid models.

253D InSight™ Tumor Penetration Screening Service
CategoryContract Research Services
Description

Tumor penetration screening service measuring antibody and drug distribution within 3D tumor spheroids.

263D InSight™ Human Beta Cell Proliferation Service
CategoryContract Research Services
Description

Service for screening compounds that promote human beta-cell proliferation using 3D islet microtissues.

273D InSight™ RNA-Seq Analysis Service
CategoryContract Research Services
Description

TempO-Seq targeted RNA sequencing service on 3D InSight™ spheroids and microtissues with BASIC, Gene Mining, and Extended analysis reports for toxicology and disease mechanism studies.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Co-development partnership behind RealBrain® Technology — a brain-specific 3D in vitro technology jointly marketed by InSphero and Tessara for scalable, human-relevant neural models used in neuroscience drug discovery.

2PharmaNest Inc.
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Strategic partnership announced in February 2026 combining InSphero's 3D spheroid models with PharmaNest's AI-powered single-fiber digital pathology platform to enable precise phenotyping of fibrotic diseases such as MASH, offering pharma/biotech customers an integrated drug efficacy screening solution that replaces animal testing with human-relevant in-vitro models.

einpresswire.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Lausanne-based DOPPL SA, an innovator in the organoid space, was acquired by InSphero AG (announced 11 November 2025). The acquisition brought DOPPL's organoid expertise and the Gri3D® hydrogel microcavity technology into InSphero's portfolio, strengthening its position in 3D cell-based assays, organ-on-chip systems, and gastrointestinal toxicity (DIGIT™ platform).

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Acquisition of Sun Bioscience's Gri3D® hydrogel microcavity technology (announced 11 November 2025) combined with the DOPPL SA deal to enhance InSphero's 3D cell model offerings, enabling scalable spheroid and organoid technologies for pharmaceutical R&D.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

PhenoVista Biosciences was acquired by InSphero AG (announced May 2026) to combine PhenoVista's high-content imaging and phenotypic assay development expertise with InSphero's scalable 3D biology platforms and AkuraFlow microphysiological systems, accelerating U.S. expansion and adoption of human-relevant in vitro technologies across pharma/biotech, with opportunities in oncology, fibrosis, neuroscience, and safety assessment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint research collaboration between ETH Zurich researchers and InSphero AG to develop a gravity-driven microfluidic platform that keeps immune cells in continuous circulation interacting with 3D tissue models for over six days, validated with primary human immune cells and tumor spheroids to improve preclinical testing of immunotherapies and antibody-based cancer treatments.

Strategic tierFlagshipTypeOthers
Description

Founding member (alongside Alveolix, BiomimX, Chiron, Dynamic42, MIMETAS, NETRI, React4Life, and TissUse) of IAMPS — the world's first industry association dedicated to representing microphysiological systems providers across Europe. IAMPS will work to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization, with operational launch in Q2 2026.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

Strategic tierMinorTypeOthers
Description

Co-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.

16U.S. FDA National Center for Toxicological Research (NCTR)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint publication / research collaboration on hepatotoxicity assessment leveraging InSphero liver microtissues; cited as a regulatory-science collaboration validating InSphero's 3D in vitro models for translational drug safety assessment.

insphero.com
17Authorized distributors (network)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distributors page on the InSphero website indicates a global network of authorized distributors reselling catalog 3D cell culture tools, microplates, and kits in regions beyond direct sales coverage.

insphero.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1CN Bio Innovations
TypeDirect peer
Description

CN Bio offers PhysioMimix™ organ-on-chip systems for liver, lung, and gut toxicology, and is named alongside InSphero among the four largest organ-on-chip market share holders. Both target pharma toxicology and DILI applications with microphysiological platforms.

TypeDirect peer
Description

Emulate is the leading organ-on-chip company (Liver-Chip S1 FDA ISTAND-validated, 87% DILI sensitivity) and is consistently listed alongside InSphero as a top organ-on-chip market share leader. Both target pharma/biotech customers with microphysiological systems for preclinical drug safety and efficacy.

TypeDirect peer
Description

TissUse develops multi-organ-on-chip systems (Humimic) for systemic toxicology and is a co-founding IAMPS member alongside InSphero. Both serve pharma/biotech with microphysiological systems aimed at replacing animal testing.

4Kirkstall
TypeEmerging player
Description

Kirkstall provides Quasi Vivo® multi-organ 3D cell culture systems that connect multiple tissue models for toxicology testing, overlapping with InSphero's Akura™ Flow and OoC offerings for pharma/biotech customers.

TypeDirect peer
Description

NETRI develops organ-on-chip and microfluidic 3D cell culture technologies for neurobiology and industrial applications, and is a co-founding member of IAMPS with InSphero. Both serve pharma/biotech with microphysiological platforms.

TypeDirect peer
Description

MIMETAS develops OrganoPlate® microfluidic 3D cell culture platforms and is one of the four leading organs-on-chips companies alongside InSphero. Both companies are founding members of IAMPS and serve pharma/biotech toxicology and disease modeling use cases.

TypeDirect peer
Description

Hesperos builds multi-organ, serum-free human-on-a-chip microphysiological systems used for toxicology and rare disease modeling, and is listed alongside InSphero as a key Disease-on-Chip market player. Both compete in pharma/biotech preclinical services.

TypeBroad incumbent
Description

Thermo Fisher is a leading life sciences tools and 3D cell culture supplier (named alongside InSphero in scaffold-free 3D cell culture market reports) and competes with InSphero's catalog tools (microplates, OoC platforms, kits) through its CellInsight, Nunc, and Gibco portfolios.

TypeEmerging player
Description

Alveolix develops lung-on-chip models for respiratory drug testing and is a co-founding IAMPS member with InSphero. Both contribute to industry-wide MPS standardization efforts relevant to InSphero's regulatory roadmap.

TypeEmerging player
Description

Dynamic42 develops organ-on-chip models with focus on inflammation, immunology, and liver applications, and is a co-founding IAMPS member. The overlap with InSphero is in microphysiological systems for pharma/biotech toxicology and disease modeling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InSphero

3D In Vitro Cell Culture and Organ-on-Chip Technologiesinsphero.com

InSphero AG is a Swiss biotechnology company that develops 3D in vitro microtissue models, organ-on-chip platforms, and contract research services for pharmaceutical and biotechnology customers seeking human-relevant, non-animal alternatives for preclinical drug discovery and safety assessment.

What InSphero does

InSphero AG is a Swiss privately held biotechnology company founded in 2009 and headquartered in Schlieren, Switzerland, with a regional operating office in Brunswick, Maine, serving the United States and Canada. The company develops 3D in vitro cell-based assay platforms — combining scaffold-free Akura™ microplates, Akura™ Organ-on-Chip microphysiological systems (Flow, Immune Flow, Twin), Gri3D® hydrogel microcavity plates (acquired from DOPPL SA / Sun Bioscience in November 2025), ARCTis™ cryopreserved 3D tumor models, and the RealBrain® neural platform co-developed with Tessara — for pharmaceutical and biotechnology customers seeking human-relevant, non-animal alternatives to preclinical drug testing. Layered on this technology base are high-content imaging (strengthened by the May 2026 PhenoVista Biosciences acquisition), TempO-Seq-based RNA sequencing modules, AI-enabled fibrosis digital pathology (via PharmaNest partnership), and a portfolio of regulatory-relevant NAMs aligned with the FDA's April 2025 Roadmap to Reducing Animal Testing and NIH organoid standardization initiatives.

InSphero operates a dual-track commercial model. Product revenue comes from catalog sales of Akura™ and Gri3D® microplates, Akura™ Organ-on-Chip platforms, the Akura™ Tilting Stand, InSphero Incubox™, and ready-to-use 3D InSight™ microtissues (liver, islet, tumor) shipped via the proprietary InFloat™ solution, distributed through the company's own e-commerce storefront (shop.insphero.com) and an authorized distributor network. Service and contract-research revenue comes from quote-based 3D InSight™ engagements — Liver Microtissues, DILI Service, DIGIT™ GI Toxicity, Translational and Investigative Toxicology, RNA-Seq reports, MASH/MASLD screening, immuno-oncology screening, therapeutic modality screening, and tumor penetration screening — priced via dedicated service schedule pages rather than published price lists.

The go-to-market is sales-led and B2B, targeting enterprise pharmaceutical and biotechnology R&D buyers through direct regional offices in Switzerland and the United States, an event-driven presence at industry venues (e.g., BIO Convention 2026 NAMs Industry Mixer), a scientific content-marketing program (peer-reviewed publications, white papers, webinars, application notes), and partnership-driven co-marketing with PharmaNest, Tessara, and ETH Zurich. The company is a founding member of IAMPS (Industry Alliance for Microphysiological Systems, expected operational Q2 2026) and holds ISO 9001:2015 certification (2023–2026). Its primary end-users are pharma/biotech R&D organizations (estimated ~55–59% of organ-on-chip demand), with secondary reach into academic and government research institutions (including a peer-reviewed collaboration with the U.S. FDA's National Center for Toxicological Research).

InSphero firmographics

Firmographics
Name
InSphero
Legal name
InSphero AG
Website
https://insphero.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
InSphero AG is a Swiss biotechnology company that develops 3D in vitro microtissue models, organ-on-chip platforms, and contract research services for pharmaceutical and biotechnology customers seeking human-relevant, non-animal alternatives for preclinical drug discovery and safety assessment.
Ownership category
akta.pro rank

InSphero industry classification

Industry
Product category
3D In Vitro Cell Culture and Organ-on-Chip Technologies
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • 3D in vitro models
  • Organ-on-chip platforms
  • Drug safety testing
  • Microphysiological systems
  • Preclinical toxicology services

Where InSphero is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

InSphero business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product sales (3D cell culture tools and microplates): One-time/perpetual-license product sales of catalog items including Akura™ 96 and 384 Spheroid Microplates, Akura™ PLUS Hanging Drop System, Gri3D® Hydrogel Microcavity Plates, Akura™ Organ-on-Chip platforms (Flow, Immune Flow, Twin), Akura™ Tilting Stand, InSphero Incubox™, and ready-to-use spheroids/kits. Distributed via own online shop (shop.insphero.com) and authorized distributors.
  2. 3D InSight™ Contract Research / Services: Fee-for-service offerings including 3D InSight™ Liver Microtissues, DILI Service Schedule, DIGIT Service Schedule, 3D InSight™ Translational Toxicology Service, 3D InSight™ Investigative Toxicology, species-specific toxicology, RNA-Seq sample reports, and 3D InSight™ Human Beta Cell Proliferation Service for pharma/biotech customers.
  3. Ready-to-use spheroids and 3D cell culture kits: Catalogue product sales of assay-ready 3D InSight™ Microtissues (liver, islet, tumor) and kits shipped via the proprietary InFloat™ shipping solution, used by pharma, biotech, and academic customers.
  4. Custom assay development and partnerships: Co-development, custom assay, and partnership revenue streams — exemplified by PharmaNest collaboration for AI-powered single-fiber digital pathology in fibrosis, and PhenoVista acquisition enabling high-content imaging assay services.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCatalog products (Akura™ microplates, Gri3D® plates, Akura™ Organ-on-Chip platforms, ready-to-use spheroids/kits) — quote-based via shop.insphero.com and distributors.
OtherPay-as-you-go3D InSight™ services (Liver Microtissues, DILI, DIGIT, RNA-Seq, Investigative Toxicology) — quote-based service engagements with production/scheduling calendars.

Go-to-market motion5 records

Distribution channels5 records

Marketing channels10 records

InSphero product offering

Product offering

Core offering

InSphero develops and sells proprietary 3D in vitro cell-based assay platforms — including scaffold-free Akura™ microplates, Gri3D® hydrogel microcavity plates, and Akura™ Organ-on-Chip microphysiological systems — alongside ready-to-use microtissues, cryopreserved 3D tumor models (ARCTis™), and contract research services (3D InSight™) for pharmaceutical and biotechnology drug discovery, toxicology, and safety assessment. The integrated product-plus-service model enables scalable, human-relevant, non-animal preclinical testing across liver safety, oncology/immuno-oncology, islet biology, gastrointestinal toxicity, fibrosis, and neuroscience applications.

Product overview

InSphero offers a single, integrated 3D in vitro platform for non-animal drug discovery and safety assessment, built around three core technologies—Akura™ Microplate Technology, Akura™ Organ-on-Chip Technology, and Gri3D® Hydrogel Microcavity Technology (acquired from DOPPL SA / Sun Bioscience)—together with the RealBrain® neural platform (partnered with Tessara) and a TempO-Seq-based RNA sequencing module. On top of this technology base, InSphero runs a portfolio of ready-to-use products and services under the 3D InSight™ brand, including 3D InSight™ Human and Species-Specific Liver Microtissues, the DILI Reference Database, 3D InSight™ Human Islet Microtissues, ARCTis™ cryopreserved patient-derived 3D tumor models, the 3D InSight™ GI Toxicity Screening Platform, and the DIGIT™ GI platform co-developed with DOPPL. Service modules—3D InSight™ Investigative Toxicology, Translational Toxicology, Predictive DILI, MASH/MASLD screening, immuno-oncology screening, antibody penetration, and tumor penetration screening—combine these microtissues with high-content imaging and AI/machine-learning analytics (notably via the PhenoVista Biosciences acquisition) to deliver human-relevant liver safety, islet biology, oncology, immunology, fibrosis, and gastrointestinal toxicology solutions for pharmaceutical and biotech R&D.

Differentiator

Problem solved

Functional benefit

Brands

  • 3D InSight™: Branded service and product line for InSphero's 3D in vitro assays and microtissue offerings (e.g., 3D InSight™ Liver Microtissues, DILI Service, Translational Toxicology Service).
  • Akura™
  • Gri3D®
  • ARCTis™
  • RealBrain®
  • InFloat™
  • InSphero Incubox™
  • DIGIT™

Products and services

  • Akura™ 96 Spheroid Microplate 96-well Akura™ microplate optimized for scaffold-free spheroid culture, enabling manual medium exchange in under two minutes and high-content imaging; sold to pharma, biotech, and academic laboratories for 3D cell culture workflows.
  • Akura™ 384 Spheroid Microplate 384-well Akura™ microplate for high-throughput scaffold-free 3D spheroid culture and screening workflows; sold to laboratories requiring scalable high-throughput 3D assays.
  • Akura™ PLUS Hanging Drop System Hanging drop system for generating and maintaining uniform 3D spheroids in a standardized, scalable format for research laboratories.
  • Gri3D® Hydrogel Microcavity Plates Standardized Gri3D® hydrogel microcavity plates supporting reproducible organoid and 3D microtissue culture with broad plate-reader and automation compatibility; sold to pharma, biotech, and academic researchers.
  • Akura™ Flow Organ-on-Chip System Perfusion microphysiological system for long-term 3D tissue culture supporting drug metabolism, DDI prediction, and chronic exposure studies; sold to pharmaceutical researchers.
  • Akura™ Immune Flow Organ-on-Chip System Microfluidic organ-on-chip that maintains immune cells in circulation while interacting with 3D tissue models for over six days via gravity-driven tilting; targets immuno-oncology and antibody-based cancer treatment research.
  • Akura™ Twin Organ-on-Chip Platform Dual-channel microphysiological platform within the Akura™ organ-on-chip family for parallel tissue conditions or multi-tissue co-culture; sold to researchers requiring comparative or multi-tissue in vitro studies.
  • Akura™ Tilting Stand Mechanical tilting stand that drives gravity-mediated perfusion in Akura™ Organ-on-Chip platforms (e.g., Akura Immune Flow), enabling pump-free circulation of immune cells.
  • InSphero Incubox™ Incubation accessory designed to maintain optimal conditions for 3D microtissue handling and short-term culture outside the incubator.
  • Akura™ 3D SureKit Ready-to-use 3D cell culture kit built on Akura™ technology for standardized liver and other 3D assay workflows.
  • ARCTis™ Cryopreserved 3D Tumor Models Cryopreserved, ready-to-use 3D tumor spheroid models for cancer research, enabling fast and reproducible testing of small molecules, biologics, and antibody penetration.
  • Ready-to-use Spheroids and 3D Cell Culture Kits Catalogue of ready-to-use spheroids, microtissues, and 3D cell culture kits delivered assay-ready with InFloat™ shipping solution; sold to pharma, biotech, and academic customers.
  • 3D InSight™ Human Liver Microtissues Assay-ready, cryopreserved and ready-to-use 3D human liver microtissues used for DILI screening, MASH/MASLD modeling, and predictive liver toxicology.
  • 3D InSight™ Species-Specific Liver Microtissues Assay-ready liver spheroids from multiple species for cross-species translational hepatotoxicity and safety pharmacology assessments.
  • 3D InSight™ Human Islet Microtissues 3D human islet microtissues for diabetes, beta-cell proliferation, and metabolic disease drug discovery.
  • 3D InSight™ GI Toxicity Screening Platform 3D in vitro gastrointestinal toxicity screening platform using human intestinal organoids in Akura™/Gri3D® plates for drug-induced GI toxicity assessment.
  • 3D InSight™ Patient-derived Primary Tumor Spheroids Platform High-throughput platform of patient-derived primary tumor spheroids for pre-clinical oncology drug discovery and screening.
  • DIGIT™ Platform Microphysiological gastrointestinal platform co-developed with DOPPL SA that combines organoid technology with InSphero's assay infrastructure for gastrointestinal research applications.
  • 3D InSight™ DILI Testing Service Advanced predictive drug-induced liver injury (DILI) testing service using 3D InSight™ liver microtissues and reference compound datasets; for pharmaceutical and biotech customers.
  • 3D InSight™ Investigative Toxicology Service Custom investigative liver safety services leveraging 3D liver microtissues for mechanism-of-action and hazard characterization studies.
  • 3D InSight™ Translational Toxicology Service Translational hepatotoxicity service combining cross-species liver microtissues, RNA-Seq, and human-relevant in vitro data to support drug development.
  • 3D In Vitro MASH Screening Service In vitro MASH (metabolic dysfunction-associated steatohepatitis) screening service for lead selection using 3D liver spheroid models.
  • 3D InSight™ Immuno-Oncology Screening Service 3D in vitro immuno-oncology screening platform using immune-competent tumor microtissues for evaluating checkpoint inhibitors, T-cell killing, and cell therapies.
  • 3D InSight™ Therapeutic Modality Screening Service Service for profiling therapeutic modalities (small molecules, antibodies, ADCs) against 3D tumor spheroid models.
  • 3D InSight™ Tumor Penetration Screening Service Tumor penetration screening service measuring antibody and drug distribution within 3D tumor spheroids.
  • 3D InSight™ Human Beta Cell Proliferation Service Service for screening compounds that promote human beta-cell proliferation using 3D islet microtissues.
  • 3D InSight™ RNA-Seq Analysis Service TempO-Seq targeted RNA sequencing service on 3D InSight™ spheroids and microtissues with BASIC, Gene Mining, and Extended analysis reports for toxicology and disease mechanism studies.

Quantifiable outcome

  • Akura™ 96 Spheroid Microplate enables manual medium exchange under 2 minutes
  • +4 more outcomes

Companies that use InSphero

Customer profile

Segments5 records

Ideal customer profiles2 records

InSphero technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability8 records

Feature9 records

InSphero partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered flagship, core and minor.

  • TessaraflagshipStrategic or Co-development PartnerCo-development partnership behind RealBrain® Technology — a brain-specific 3D in vitro technology jointly marketed by InSphero and Tessara for scalable, human-relevant neural models used in neuroscience drug discovery.
  • PharmaNest Inc.flagshipStrategic or Co-development PartnerStrategic partnership announced in February 2026 combining InSphero's 3D spheroid models with PharmaNest's AI-powered single-fiber digital pathology platform to enable precise phenotyping of fibrotic diseases such as MASH, offering pharma/biotech customers an integrated drug efficacy screening solution that replaces animal testing with human-relevant in-vitro models.
  • DOPPL SAflagshipStrategic or Co-development PartnerLausanne-based DOPPL SA, an innovator in the organoid space, was acquired by InSphero AG (announced 11 November 2025). The acquisition brought DOPPL's organoid expertise and the Gri3D® hydrogel microcavity technology into InSphero's portfolio, strengthening its position in 3D cell-based assays, organ-on-chip systems, and gastrointestinal toxicity (DIGIT™ platform).
  • Sun BioscienceflagshipStrategic or Co-development PartnerAcquisition of Sun Bioscience's Gri3D® hydrogel microcavity technology (announced 11 November 2025) combined with the DOPPL SA deal to enhance InSphero's 3D cell model offerings, enabling scalable spheroid and organoid technologies for pharmaceutical R&D.
  • PhenoVista Biosciences, Inc.flagshipStrategic or Co-development PartnerPhenoVista Biosciences was acquired by InSphero AG (announced May 2026) to combine PhenoVista's high-content imaging and phenotypic assay development expertise with InSphero's scalable 3D biology platforms and AkuraFlow microphysiological systems, accelerating U.S. expansion and adoption of human-relevant in vitro technologies across pharma/biotech, with opportunities in oncology, fibrosis, neuroscience, and safety assessment.
  • ETH ZurichcoreStrategic or Co-development PartnerJoint research collaboration between ETH Zurich researchers and InSphero AG to develop a gravity-driven microfluidic platform that keeps immune cells in continuous circulation interacting with 3D tissue models for over six days, validated with primary human immune cells and tumor spheroids to improve preclinical testing of immunotherapies and antibody-based cancer treatments.
  • IAMPS (Industry Alliance for Microphysiological Systems)flagshipOthersFounding member (alongside Alveolix, BiomimX, Chiron, Dynamic42, MIMETAS, NETRI, React4Life, and TissUse) of IAMPS — the world's first industry association dedicated to representing microphysiological systems providers across Europe. IAMPS will work to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization, with operational launch in Q2 2026.
  • AlveolixminorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • BiomimXminorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • ChironminorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • Dynamic42minorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • MIMETASminorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • NETRIminorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • React4LifeminorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • TissUseminorOthersCo-founding member of IAMPS alongside InSphero, contributing to industry-wide efforts on regulatory acceptance, data sharing, and device standardization for microphysiological systems.
  • U.S. FDA National Center for Toxicological Research (NCTR)coreStrategic or Co-development PartnerJoint publication / research collaboration on hepatotoxicity assessment leveraging InSphero liver microtissues; cited as a regulatory-science collaboration validating InSphero's 3D in vitro models for translational drug safety assessment.
  • Authorized distributors (network)coreChannel Partner/ Reseller/ DistributorDistributors page on the InSphero website indicates a global network of authorized distributors reselling catalog 3D cell culture tools, microplates, and kits in regions beyond direct sales coverage.

Scale indicators15 records

Recent moves6 records

Expansion highlights7 records

InSphero competitors and assessment

Company assessment

Direct peers

  • CN Bio Innovations: CN Bio offers PhysioMimix™ organ-on-chip systems for liver, lung, and gut toxicology, and is named alongside InSphero among the four largest organ-on-chip market share holders. Both target pharma toxicology and DILI applications with microphysiological platforms.
  • Emulate: Emulate is the leading organ-on-chip company (Liver-Chip S1 FDA ISTAND-validated, 87% DILI sensitivity) and is consistently listed alongside InSphero as a top organ-on-chip market share leader. Both target pharma/biotech customers with microphysiological systems for preclinical drug safety and efficacy.
  • TissUse: TissUse develops multi-organ-on-chip systems (Humimic) for systemic toxicology and is a co-founding IAMPS member alongside InSphero. Both serve pharma/biotech with microphysiological systems aimed at replacing animal testing.
  • NETRI: NETRI develops organ-on-chip and microfluidic 3D cell culture technologies for neurobiology and industrial applications, and is a co-founding member of IAMPS with InSphero. Both serve pharma/biotech with microphysiological platforms.
  • MIMETAS: MIMETAS develops OrganoPlate® microfluidic 3D cell culture platforms and is one of the four leading organs-on-chips companies alongside InSphero. Both companies are founding members of IAMPS and serve pharma/biotech toxicology and disease modeling use cases.
  • Hesperos: Hesperos builds multi-organ, serum-free human-on-a-chip microphysiological systems used for toxicology and rare disease modeling, and is listed alongside InSphero as a key Disease-on-Chip market player. Both compete in pharma/biotech preclinical services.

Emerging players

  • Kirkstall: Kirkstall provides Quasi Vivo® multi-organ 3D cell culture systems that connect multiple tissue models for toxicology testing, overlapping with InSphero's Akura™ Flow and OoC offerings for pharma/biotech customers.
  • Alveolix: Alveolix develops lung-on-chip models for respiratory drug testing and is a co-founding IAMPS member with InSphero. Both contribute to industry-wide MPS standardization efforts relevant to InSphero's regulatory roadmap.
  • Dynamic42: Dynamic42 develops organ-on-chip models with focus on inflammation, immunology, and liver applications, and is a co-founding IAMPS member. The overlap with InSphero is in microphysiological systems for pharma/biotech toxicology and disease modeling.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher is a leading life sciences tools and 3D cell culture supplier (named alongside InSphero in scaffold-free 3D cell culture market reports) and competes with InSphero's catalog tools (microplates, OoC platforms, kits) through its CellInsight, Nunc, and Gibco portfolios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

InSphero social profiles

Digital presence

InSphero compliance and trust

Trust signal

Compliance1 record

InSphero financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InSphero leadership team

Management profile

Number of profiles

Profiles4 records

InSphero subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

InSphero funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InSphero M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InSphero

What does InSphero do?

InSphero develops and sells proprietary 3D in vitro cell-based assay platforms — including scaffold-free Akura™ microplates, Gri3D® hydrogel microcavity plates, and Akura™ Organ-on-Chip microphysiological systems — alongside ready-to-use microtissues, cryopreserved 3D tumor models (ARCTis™), and contract research services (3D InSight™) for pharmaceutical and biotechnology drug discovery, toxicology, and safety assessment. The integrated product-plus-service model enables scalable, human-relevant, non-animal preclinical testing across liver safety, oncology/immuno-oncology, islet biology, gastrointestinal toxicity, fibrosis, and neuroscience applications.

Is InSphero a public or private company?

InSphero is a private company. It is classified as venture growth investor backed and is currently operating.

When was InSphero founded?

InSphero was founded in 2009. It employs 51 to 100 people.

Where is InSphero based?

InSphero is headquartered in Schlieren, Switzerland, in the Europe region.

How does InSphero make money?

Four revenue lines are on record. Product sales (3D cell culture tools and microplates) is the primary driver. The others are 3D InSight™ Contract Research / Services, ready-to-use spheroids and 3D cell culture kits and custom assay development and partnerships.

Who are InSphero's main competitors?

Direct peers on record are CN Bio Innovations, Emulate, TissUse, NETRI, MIMETAS and Hesperos. Emerging players are Kirkstall, Alveolix and Dynamic42. Thermo Fisher Scientific is listed as a broad incumbent.

Does InSphero have an API?

No public API is recorded for InSphero.

What industry is InSphero in?

InSphero's product category is 3D In Vitro Cell Culture and Organ-on-Chip Technologies. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chThree Swiss biotechs promote from withinThree Swiss biotechs promoted senior roles from within: Avrion appointed co-founder Maximilien Murone interim CEO in June, while InSphero elevated Olivier Frey to combined COO and CTO and Opterion Health named Ulrike Maria Grimm chief development officer. Avrion's lead programme AVR-001 targets SOD1-linked ALS in IND-enabling studies, and Opterion's OPT101 entered its Phase 1 SPARC trial in February.Technology NetworksHow Preclinical Models Are Failing Oncology— And Why Patient‑Derived Organoids Might Finally Fix ItExperts warn that traditional preclinical models, particularly patient-derived xenografts in immunodeficient mice, are too biologically homogeneous to capture the heterogeneity of real patients, causing viable drug candidates to be deprioritized due to false negatives. Dr. Madhu Lal-Nag, Chief Scientific Officer at InSphero, argues that patient-derived organoids and other complex in vitro models preserve tumor biology more faithfully, enabling identification of responder subpopulations that animal models average out. A 2019 FDA regulatory shift and the agency's April 2025 Roadmap to Reducing Animal Testing signal growing momentum toward human-relevant models paired with AI-driven prediction in oncology R&D.startupticker.chInSphero acquires PhenoVista to expand US presenceInSphero has acquired PhenoVista Biosciences, a California-based contract research organization, to expand its operations in the United States. The deal combines InSphero's 3D in vitro models with PhenoVista's high-content imaging and phenotypic analysis capabilities to enhance drug discovery services. This transaction follows InSphero's recent acquisition of DOPPL and aligns with growing US demand for New Approach Methodologies.Pulse 2.0InSphero: PhenoVista Biosciences Acquisition Expands 3D Cell-Based Assay And Imaging CapabilitiesInSphero AG announced the acquisition of PhenoVista Biosciences, Inc., combining PhenoVista's expertise in high-content imaging and phenotypic assay development with InSphero's scalable 3D biology platforms and AkuraFlow microphysiological systems. The merged entity aims to deliver integrated 3D biology, high-content imaging, and AI-enabled analytics workflows to pharmaceutical and biotechnology customers across oncology, fibrosis, neuroscience, and safety assessment research. InSphero noted that recent U.S. policy support for New Approach Methodologies from the FDA and NIH is creating a favorable environment for broader adoption of human-relevant in vitro technologies.BioSpaceInSphero AG Acquires PhenoVista Biosciences, Inc. to Expand Advanced 3D, Cell-based Assay CapabilitiesInSphero AG has acquired PhenoVista Biosciences, Inc., a San Diego-based provider of high-content imaging and phenotypic assay technologies. This strategic move aims to combine InSphero's 3D microtissue platforms with PhenoVista's imaging expertise to accelerate the adoption of predictive drug discovery workflows. The combined organization intends to expand its global commercial infrastructure and offer integrated solutions for oncology, neuroscience, and safety assessment.EIN PresswireInSphero Accelerates Global Growth and US Expansion with Acquisition of PhenoVista BiosciencesInSphero acquired California-based PhenoVista Biosciences, a provider of high-content imaging and phenotypic assay technologies. The deal strengthens InSphero's US presence and expands capabilities in neuroscience and neurotoxicity testing. The acquisition follows the recent purchase of DOPPL SA.InspheroInSphero Accelerates US Expansion with PhenoVistaInSphero acquired California-based PhenoVista Biosciences, a provider of high-content imaging and phenotypic assay services. The deal strengthens InSphero's US presence and expands capabilities in oncology, neuroscience, and safety assessment. The acquisition follows the recent purchase of DOPPL SA.SdbnInSphero AG Acquires PhenoVista Biosciences, Inc. to Expand Advanced 3D, Cell-based Assay Capabilities – San Diego Biotechnology NetworkInSphero AG acquired PhenoVista Biosciences, a San Diego-based provider of high-content imaging and phenotypic assay technologies. The acquisition aims to expand PhenoVista's scientific and commercial impact in advanced 3D cell-based assays.Business Wire BlogInSphero AG Acquires PhenoVista Biosciences, Inc. to Expand Advanced 3D, Cell-based Assay CapabilitiesInSphero AG announced the acquisition of PhenoVista Biosciences, Inc. to enhance its capabilities in advanced 3D, cell-based assays. This acquisition aims to combine PhenoVista's imaging and assay development expertise with InSphero's 3D modeling strengths, ultimately enhancing drug discovery and toxicology workflows. The combined entity intends to leverage new methodologies and technologies to create more predictive environments for drug development.